Strength Training Is Key Make strength training a part of your weekly routine
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes, administered as a once-weekly subcutaneous injection
Sadowska-Przytocka A, Gruszczyska M, Ostaowska A, Antosik P, Czarnecka-Operacz M, Adamski Z, cka K
Maintaining higher metabolic rate during active weight loss and weight maintenance phases represents a significant advantage over dietary restriction alone
Armed with this knowledge, making an informed choice becomes much simpler, ensuring that individuals can find a medication tailored to their specific health needs
That said, compounded liraglutide*, an older GLP-1 medication, is still permitted and may be a viable option for some patients in cases when FDA-approved liraglutide products (like Saxenda and Victoza) are unavailable or unsuitable